Glioblastoma Recurrence after Cediranib Therapy in Patients: Lack of “Rebound” Revascularization as Mode of Escape

Recurrent glioblastomas (rGBM) invariably relapse after initial response to anti-VEGF therapy. There are two prevailing hypotheses on how these tumors escape antiangiogenic therapy: switch to VEGF-independent angiogenic pathways and vessel co-option. However, direct evidence in rGBM patients is lack...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: di Tomaso, Emmanuelle, Snuderl, Matija, Kamoun, Walid S., Duda, Dan G., Auluck, Pavan K., Fazlollahi, Ladan, Andronesi, Ovidiu C., Frosch, Matthew P., Wen, Patrick Y., Plotkin, Scott R., Hedley-Whyte, E. Tessa, Sorensen, A. Gregory, Batchelor, Tracy T., Jain, Rakesh K.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2011
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3074948/
https://ncbi.nlm.nih.gov/pubmed/21199795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-10-2602
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge